Physician
Psychiatry
Dr. George P. Gardos, MD
|
|
Give Review
George P. Gardos, MD is an expert in the field of Psychiatry. Dr. George P. Gardos is also published. He has 79 publications published. The lastest publication: "The evaluation and treatment of neuroleptic-induced movement disorders.' He is registered with Medicare and accepts Medicare payments.
Publications
- Long-term treatment of panic Disorder with agoraphobia in private practice.
- TWO CASES OF SUBDURAL HAEMATOMA COMPLICATING ANTICOAGULANT THERAPY.
- [Potassium permeability of the human red blood cells].
- Potassium accumulation in guinea pig brain cortex slices.
- The function of calcium in the regulation of potassium accumulation in guinea pig brain cortex slices.
- The role of calcium in the potassium permeability of human erythrocytes.
- The function of calcium in the potassium permeability of human erythrocytes.
- Effect of ethylenediaminetetraacetate on the permeability of human erythrocytes.
- [The role of adenosine-triphosphoric acid (ATP) in the potassium permeability of human erythrocytes].
- [Potassium permeability of human erythrocytes].
- Managing antipsychotic-induced tardive dyskinesia.
- The evaluation and treatment of neuroleptic-induced movement Disorders.
- Reversible dyskinesia during bupropion therapy.
- Global diagnostic ratings compared to DSM-III-R diagnoses in early dyskinesia.
- Ten-year outcome of tardive dyskinesia.
- Dystonic reaction during maintenance antipsychotic therapy.
- The Oral Board Examination: a call for its demise.
- Disinhibition of behavior by antianxiety drugs.
- A 12-year follow-up study of chronic schizophrenics.
- Alexithymia: towards validation and measurement.
- Undiagnosed dystonic reaction secondary to amoxapine.
- Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
- Tardive dyskinesia: changes after three years.
- The prognosis of tardive dyskinesia.
- Changes in extrapyramidal symptoms following anticholinergic drug withdrawal.
- Tardive dyskinesia and anticholinergic drugs.
- Adverse effects of antiparkinson drug withdrawal.
- Clonazepam and phenobarbital in tardive dyskinesia.
- Absence of severe tardive dyskinesia in Hungarian schizophrenic out-patients.
- Overview: public health issues in tardive dyskinesia.
- Trifluoperazine and chlorpromazine in combination and individually.
- Thiothixene and trifluoperazine in a step system.
- Differential actions of chlordiazepoxide and oxazepam on hostility.
- The dual action of thiothixene.
- The need for feedback to authors.
- CNS effects of propranolol in man.
- Are antipsychotic drugs interchangeable?
- Evaluation of pyrovalerone in chronically fatigued volunteers.
- Tybamate: an examination of its actions in "high" and "low" anxious normals.
- A pilot study of ORF 8063, a new benzodiazepine in anxious alcoholic patients.
- A controlled evaluation of pyrovalerone in chronically fatigued volunteers.
- A dose-response study of propranolol in chronic schizophrenics.
- The importance of dosage in antipsychotic drug administration--a review of dose-response studies.
- The maximal velocity and the calcium affinity of the red cell calcium pump may be regulated independently.
- Seven-year follow-up of tardive dyskinesia in Hungarian outpatients.
- The natural history of tardive dyskinesia.
- Comparison of severe and mild tardive dyskinesia: implications for etiology.
- Clinical forms of severe tardive dyskinesia.
- Five-year follow-up study of tardive dyskinesia.
- Functional domains of the in situ red cell membrane calcium pump revealed by proteolysis and monoclonal antibodies. Possible sites for regulation by calpain and acidic...
- A forgotten antipsychotic.
- Calmodulin-binding domains from isozymes of the plasma membrane Ca2+ pump have different regulatory properties.
- Early dyskinesia--vulnerability.
- The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia.
- Quantitative assessment of psychomotor activity in patients with neuroleptic-induced akathisia.
- Eye color and tardive dyskinesia.
- Letter: Papaverine for tardive dyskinesia?
- The assessment of tardive dyskinesia.
- Weight reduction in schizophrenics by molindone.
- An evaluation of papaverine in tardive dyskinesia.
- Treatment with mesoridazine and thioridazine in chronic Schizophrenia: II. Potential predictors of drug response.
- Treatment with mesoridazine and thioridazine in chronic Schizophrenia: I. Assessment of clinical and electrophysiologic responses in refractory hallucinating schizophr...
- A case of withdrawal dyskinesia.
- Sex and psychiatry.
- A CNV typology of chronic schizophrenics and response to drug treatment.
- The effects of papaverine in tardive dyskinesia.
- Pilot study of cyproheptadine (Periactin) in tardive dyskinesia [proceedings].
- Doxepin or diazepam for anxious and anxious-depressed outpatients?
- ACTH 4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome.
- ACTH4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome.
- A rating scale for tardive dyskinesia.
- Placebo response, placebo effect, and two attributes.
- Dyskinesia after discountinuation of compound analgesic containing oxycodone.
- Drug variables in the etiology of tardive dyskinesia application of discriminant function analysis.
- Withdrawal syndromes associated with antipsychotic drugs.
- Maintenance antipsychotic therapy: is the cure worse than the disease?
- High and low dose thiothixene treatment in chronic Schizophrenia.
- Antipsychotic polypharmacy or monotherapy?
Procedures Preformed
- Psychotherapy and Psychophysiological Therapy (incl. Biofeedback)
Conditions Treated
- Bipolar Disorder
- Dysthymia and Cyclothymia (Mood Disorders)
- Schizophrenia
Doctors Specialties
- Psychiatry
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Commercial Insurance Company
- Harvard Pilgrim Health Care PPO
- Medicare MCR
Education
-
Beth Israel Deaconess Medical Center
Hospital
-
McLean Hospital
Drug Facts
| NPI NUMBER | 1487678801 | |
| NPPES Provider LastName | GARDOS | |
| NPPES Provider FirstName | GEORGE | |
| NPPES Provider ZIPCode | 023011168 | |
| NPPES Provider State | MA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 3114.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1487678801 |
| Last Name Of The Provider | GARDOS |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. David Z. Starr, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Ione G. Milner, LICSW |
|
|
Dr. Joshua P. Golden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Krishnaswamy Gajaraj, MD
This Doctor is OpenDoctor Recommended.
|